Amoxicillin/Clavulanate
(Redirected from Augmentin)
General
- Type: Amino-Penicillin
- Dosage Forms: oral suspension, tablet, extended release tablet, chewable tablet
- Dosage Strengths: oral suspension: (125/31.25mg)/5mL, (200mg/28.5mg)/5mL, (250mg/62.5mg)/5mL, (400mg/57mg)/5mL, (600mg/42.9mg)/5mL; tablet: 250mg/125mg, 500mg/125mg, 875mg/125mg; extended release tablet: 1000mg/62.5mg; chewable tablet: 200mg/28.5mg, 400mg/57mg
- Routes of Administration: PO
- Common Trade Names: Augmentin, Augmentin XR, Augmentin ES-600
Adult Dosing
Infection, Bacterial
- 500mg-875mg PO q12h
Pneumonia, community-acquired
- 2000mg ER PO q12h x 7-10 days
Pediatric Dosing
Infection, Bacterial
- 25-45mg/kg PO divided q12h
Otitis media
- 90mg/kg/day PO divided q12h x 10 days
Special Populations
- Pregnancy risk: B
- Lactation: probably safe
- Renal Dosing
- Adult: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Pediatric: CrCl 10-30: give q12h, CrCl < 10, give q24h
- Hepatic Dosing
- Adult: none
- Pediatric: none
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Anaphylaxis
- Steven Johnson syndrome
- C. diff associated diarrhea
- Hemolytic anemia
- Leukopenia
- Thrombocytopenia
- Hepatitis
- Seizures
Common
- Diarrhea
- Nausea and vomiting
- Rash
- Pruritus
- Glossitis
- Transaminitis
Pharmacology
- Half-life: 1.1 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action:Bactericidal, inhibits cell wall mucopeptide synthesis, inhibits beta lactamases
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014